Role of Galectins in Multiple Myeloma

Galectins are a family of lectins that bind β-galactose-containing glycoconjugates and are characterized by carbohydrate-recognition domains (CRDs). Galectins exploit several biological functions, including angiogenesis, regulation of immune cell activities and cell adhesion, in both physiological a...

Full description

Bibliographic Details
Main Authors: Paola Storti, Valentina Marchica, Nicola Giuliani
Format: Article
Language:English
Published: MDPI AG 2017-12-01
Series:International Journal of Molecular Sciences
Subjects:
Online Access:https://www.mdpi.com/1422-0067/18/12/2740
_version_ 1811281242575863808
author Paola Storti
Valentina Marchica
Nicola Giuliani
author_facet Paola Storti
Valentina Marchica
Nicola Giuliani
author_sort Paola Storti
collection DOAJ
description Galectins are a family of lectins that bind β-galactose-containing glycoconjugates and are characterized by carbohydrate-recognition domains (CRDs). Galectins exploit several biological functions, including angiogenesis, regulation of immune cell activities and cell adhesion, in both physiological and pathological processes, as tumor progression. Multiple myeloma (MM) is a plasma cell (PC) malignancy characterized by the tight adhesion between tumoral PCs and bone marrow (BM) microenvironment, leading to the increase of PC survival and drug resistance, MM-induced neo-angiogenesis, immunosuppression and osteolytic bone lesions. In this review, we explore the expression profiles and the roles of galectin-1, galectin-3, galectin-8 and galectin-9 in the pathophysiology of MM. We focus on the role of these lectins in the interplay between MM and BM microenvironment cells showing their involvement in MM progression mainly through the regulation of PC survival and MM-induced angiogenesis and osteoclastogenesis. The translational impact of these pre-clinical pieces of evidence is supported by recent data that indicate galectins could be new attractive targets to block MM cell growth in vivo and by the evidence that the expression levels of LGALS1 and LGALS8, genes encoding for galectin-1 and galectin-8 respectively, correlate to MM patients’ survival.
first_indexed 2024-04-13T01:30:14Z
format Article
id doaj.art-c18b3559852c4388a0f46bc251a0a00b
institution Directory Open Access Journal
issn 1422-0067
language English
last_indexed 2024-04-13T01:30:14Z
publishDate 2017-12-01
publisher MDPI AG
record_format Article
series International Journal of Molecular Sciences
spelling doaj.art-c18b3559852c4388a0f46bc251a0a00b2022-12-22T03:08:32ZengMDPI AGInternational Journal of Molecular Sciences1422-00672017-12-011812274010.3390/ijms18122740ijms18122740Role of Galectins in Multiple MyelomaPaola Storti0Valentina Marchica1Nicola Giuliani2Department of Medicine and Surgery, University of Parma, Via Gramsci, 14, 43126 Parma, ItalyDepartment of Medicine and Surgery, University of Parma, Via Gramsci, 14, 43126 Parma, ItalyDepartment of Medicine and Surgery, University of Parma, Via Gramsci, 14, 43126 Parma, ItalyGalectins are a family of lectins that bind β-galactose-containing glycoconjugates and are characterized by carbohydrate-recognition domains (CRDs). Galectins exploit several biological functions, including angiogenesis, regulation of immune cell activities and cell adhesion, in both physiological and pathological processes, as tumor progression. Multiple myeloma (MM) is a plasma cell (PC) malignancy characterized by the tight adhesion between tumoral PCs and bone marrow (BM) microenvironment, leading to the increase of PC survival and drug resistance, MM-induced neo-angiogenesis, immunosuppression and osteolytic bone lesions. In this review, we explore the expression profiles and the roles of galectin-1, galectin-3, galectin-8 and galectin-9 in the pathophysiology of MM. We focus on the role of these lectins in the interplay between MM and BM microenvironment cells showing their involvement in MM progression mainly through the regulation of PC survival and MM-induced angiogenesis and osteoclastogenesis. The translational impact of these pre-clinical pieces of evidence is supported by recent data that indicate galectins could be new attractive targets to block MM cell growth in vivo and by the evidence that the expression levels of LGALS1 and LGALS8, genes encoding for galectin-1 and galectin-8 respectively, correlate to MM patients’ survival.https://www.mdpi.com/1422-0067/18/12/2740galectinsmyelomagalectin-1galectin-3galectin-8galectin-9
spellingShingle Paola Storti
Valentina Marchica
Nicola Giuliani
Role of Galectins in Multiple Myeloma
International Journal of Molecular Sciences
galectins
myeloma
galectin-1
galectin-3
galectin-8
galectin-9
title Role of Galectins in Multiple Myeloma
title_full Role of Galectins in Multiple Myeloma
title_fullStr Role of Galectins in Multiple Myeloma
title_full_unstemmed Role of Galectins in Multiple Myeloma
title_short Role of Galectins in Multiple Myeloma
title_sort role of galectins in multiple myeloma
topic galectins
myeloma
galectin-1
galectin-3
galectin-8
galectin-9
url https://www.mdpi.com/1422-0067/18/12/2740
work_keys_str_mv AT paolastorti roleofgalectinsinmultiplemyeloma
AT valentinamarchica roleofgalectinsinmultiplemyeloma
AT nicolagiuliani roleofgalectinsinmultiplemyeloma